about
ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genomeThe BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancerA perspective view of sodium iodide symporter research and its clinical implicationsAssociation between BRAF V600E mutation and recurrence of papillary thyroid cancer.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.Molecular biology of thyroid cancer initiation.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis.Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).DNA methylation signatures identify biologically distinct thyroid cancer subtypes.Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors.[Severe polymyositis with simvastatin use]Clinical guidelines for management of thyroid nodule and cancer during pregnancy.BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer.Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.NIS mediates iodide uptake in the female reproductive tract and is a poor prognostic factor in ovarian cancer.Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer.[Use of new molecules in the treatment of advanced thyroid cancer].BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerThe oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneComments to SEOM clinical guidelines for the treatment of thyroid cancerTreatment of thyroid cancer with the new oral agentsBRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinomaHsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicingImpaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness
P50
Q28078220-2A428186-88A0-4E10-9A76-628A288D5B22Q28262702-24F1CB5E-8271-4E56-B9A7-22EB43C747E7Q28264871-B4AA48CF-23E2-4B17-848B-451A3F7047C3Q34716574-6E2FDC5E-ACEE-4F22-929A-526D8F9031EEQ36431628-378624E6-EAC0-47A9-A36E-DB544BBB9273Q37018396-7626233F-ED79-4C1B-8E79-E6C45063B76AQ37022649-E02A72FE-74D1-4528-8188-BE02ACD069E2Q37216703-693AFEEA-C356-4B2C-A74D-FDC087943834Q37580248-646FD75A-81DE-4600-853C-5E863075DB4EQ38316467-ECC8A551-626A-4FB7-BA57-5AAA4E554F02Q38366842-DA3CEAFB-7BA0-48D5-BFDD-6C378EC48E13Q38743211-602DF570-FAFD-4399-9C97-A6EFD33E49D0Q38798863-5AE6E9E7-8567-4A56-9281-46E11787D1BDQ38843109-FFF7D383-26B1-48CC-9EC5-188871F6A237Q38972528-AF3614E3-2F90-47F1-9F88-B22141C2639FQ39153033-9C9C806C-0040-40DE-89F3-EB2BBF0BA8A6Q39520055-56607263-0F45-479F-A7CD-AB4BE7BA935EQ41346876-491AA89C-7D80-40AE-A3C7-0F85B18D00C0Q44667022-2A98A3F8-015C-49DE-A730-48C4A8D89F0CQ45728864-6C5BC044-346D-4EDA-B3D8-1B9BB7581C73Q49808093-1D188E21-09EA-4B55-A7CD-1B6D10749AF4Q49808140-0B28807B-A35F-4B42-B001-BF58D74CE6D1Q50438414-738A8951-71BF-4955-A74F-FF4821E7290EQ51148384-3F671211-9946-4A02-97BF-7E376E7B44F6Q54232191-CB5BDF85-11E6-44BF-8637-B8213DA3BD22Q54559637-44943CF4-4240-4E83-9027-BB424278B642Q58802686-126FD25A-D5DA-4871-A5CB-F51C18C5D900Q60559931-D9DB990D-8FD6-48AC-B868-D5C074109F81Q84705100-AD79574D-CEB9-4B79-A538-55C5334449F0Q84806837-9AC9FF62-FB46-4696-9F54-95EDEA0A9710Q91608758-3B17391A-156A-4B70-B868-3F34F8F08EE7Q92558531-AFAD77DE-610C-47AD-8B25-550B8CEB2286Q92987363-0A84F933-8F0D-4712-B8FE-F1418CACD016
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Garcilaso Riesco-Eizaguirre
@ast
Garcilaso Riesco-Eizaguirre
@en
Garcilaso Riesco-Eizaguirre
@es
Garcilaso Riesco-Eizaguirre
@nl
Garcilaso Riesco-Eizaguirre
@sl
type
label
Garcilaso Riesco-Eizaguirre
@ast
Garcilaso Riesco-Eizaguirre
@en
Garcilaso Riesco-Eizaguirre
@es
Garcilaso Riesco-Eizaguirre
@nl
Garcilaso Riesco-Eizaguirre
@sl
prefLabel
Garcilaso Riesco-Eizaguirre
@ast
Garcilaso Riesco-Eizaguirre
@en
Garcilaso Riesco-Eizaguirre
@es
Garcilaso Riesco-Eizaguirre
@nl
Garcilaso Riesco-Eizaguirre
@sl
P1053
O-8750-2015
P106
P31
P496
0000-0002-2608-6397